Bisphosphonates and Bone Density: What Your DEXA Scan Reveals About Whether Your Osteoporosis Treatment Is Working
Your GP prescribed alendronic acid several months ago, and you are wondering whether it is actually making a difference. You are not alone. Bisphosphonates remain the most commonly prescribed treatment for osteoporosis in the UK. Yet many patients never receive a follow-up scan to confirm the medication is working. A bone density DEXA scan is the only reliable way to measure whether your bones are responding to treatment.
Quick answer: Bisphosphonates such as alendronic acid typically increase bone density at the spine by 5 to 7 per cent over three years. At the hip, gains are roughly 3 to 6 per cent over the same period. A follow-up DEXA scan after two to three years of treatment is the clinical standard for confirming your bones are responding.
How Bisphosphonates Work to Protect Your Bones
Bisphosphonates slow down the osteoclasts. These are the cells that break down bone tissue. By reducing the rate of bone resorption, the medication tips the balance in favour of bone formation. This allows density to gradually recover.
The most commonly prescribed oral bisphosphonate in the UK is alendronic acid (brand name Fosamax). It is usually taken as a 70 mg tablet once a week. Risedronate and ibandronate are also used. Intravenous options such as zoledronic acid (given once a year) are available for patients who cannot tolerate oral forms.
The effect is not immediate. Bone is living tissue that remodels slowly. Measurable changes on a DEXA scan typically take 18 to 24 months to appear. This is why scanning too early can be misleading and why patience during the first phase of treatment is important.
What Your DEXA Scan Should Show After Treatment
Clinical trials, including the landmark Fracture Intervention Trial (FIT), provide clear benchmarks for what bisphosphonate therapy should achieve. Over roughly three years, alendronate and risedronate increase lumbar spine density by about 5 to 7 per cent. Hip density gains are roughly 3 to 6 per cent. These gains are associated with a 30 to 50 per cent reduction in vertebral and hip fractures.
Over ten years of continuous treatment, alendronate increases lumbar spine density by about 13.7 per cent. Total hip density rises by about 6.7 per cent.
It is important to understand that even stable bone density counts as a positive treatment response. If your T-score has stopped falling, the medication is doing its job. Preventing further loss is as clinically meaningful as gaining density. It still reduces your fracture risk significantly.
When to Have a Follow-Up DEXA Scan
Most clinical guidelines agree that a follow-up DEXA scan should not be performed earlier than two years after starting bisphosphonate therapy. The reason is technical. DEXA machines have a measurement precision of around 1 to 2 per cent at the hip. The minimum change that can be reliably detected is called the least significant change (LSC). This is approximately 3 to 6 per cent. Scanning at one year risks showing changes within the margin of error. This can cause unnecessary anxiety or prompt inappropriate treatment changes.
For most patients on bisphosphonates, the first follow-up scan should happen two to three years after starting treatment. If treatment continues, repeat scans every two to three years help track progress. At the five-year mark, a full reassessment of fracture risk is recommended. This review typically includes a repeat DEXA alongside a FRAX score recalculation. It helps your clinician decide whether to continue treatment or consider a drug holiday.
What If Your Bone Density Has Not Improved
A DEXA result that shows no change should not be interpreted as treatment failure. The same applies to a small decline within the least significant change. Before adjusting medication, your clinician should first check a few things. Are you taking the tablet correctly? That means on an empty stomach, with plain water, and staying upright for at least 30 minutes. Is your calcium and vitamin D intake adequate? Are you doing regular weight-bearing exercise? Could a secondary cause of bone loss be present, such as an overactive thyroid, hyperparathyroidism, or coeliac disease?
If bone density has genuinely fallen beyond the LSC after two to three years of consistent therapy, this may indicate an inadequate response. Options include switching to a different bisphosphonate or moving to denosumab (a six-monthly injection). For severe cases, anabolic treatments such as teriparatide may be considered. Your clinician will guide this decision based on your full clinical picture.
Drug Holidays: When Stopping Treatment May Be Appropriate
After five years of oral bisphosphonate therapy, current UK guidance recommends reviewing whether continued treatment is necessary. If your fracture risk has fallen close to the intervention threshold and your T-score has risen above minus 2.5, a drug holiday may be appropriate.
During a drug holiday, bisphosphonates remain stored in bone tissue. They continue to exert a protective effect for one to two years. A repeat DEXA scan at the end of the holiday period determines whether treatment needs to restart.
Some patients remain at high risk after five years. This includes those with a history of vertebral fractures or persistently low T-scores. These patients should generally continue treatment indefinitely. The benefit of ongoing fracture prevention outweighs the small risk of rare side effects such as atypical femoral fracture.
Frequently Asked Questions
How long does it take for bisphosphonates to show results on a DEXA scan?
Measurable changes typically require 18 to 24 months. Most clinicians recommend waiting at least two years before repeating a DEXA scan to assess treatment response.
Can bisphosphonates increase my bone density to normal levels?
Some patients do see their T-score return to the normal range (above minus 1.0). This depends on how severe bone loss was at diagnosis, the specific medication, and how long treatment continues. Even modest gains significantly reduce fracture risk.
Do I need to take calcium and vitamin D alongside bisphosphonates?
Yes. Bisphosphonates work by slowing bone breakdown, but your body still needs calcium and vitamin D to build new bone. Most UK guidelines recommend around 1,000 mg of calcium and 800 to 1,000 IU of vitamin D daily during treatment.
What happens if I stop taking bisphosphonates?
Bisphosphonates are stored in bone and continue to have some protective effect for one to two years after stopping. This is unlike denosumab, which causes rapid bone loss when discontinued. However, bone density will eventually begin to decline again. Regular monitoring with DEXA remains important even during a drug holiday.
What This Means for You
If you are taking a bisphosphonate for osteoporosis, a follow-up DEXA scan is one of the most valuable steps you can take. It confirms whether your treatment is working. It guides decisions about continuing or pausing medication. And it gives you and your clinician objective data rather than guesswork. Most patients on bisphosphonates should have their first follow-up scan two to three years after starting treatment.
At DEXA London, we provide clinical-grade bone density DEXA scans at our Harley Street clinic. Whether you are starting treatment, monitoring your progress, or reviewing your medication after a drug holiday, we can help. A DEXA scan gives you the numbers you need for informed decisions about your bone health.
If you were first diagnosed with osteopenia, our guide to osteopenia and what your DEXA T-score means explains the thresholds that led to your prescription.
To book your scan, visit our bone density scanning page or call us on 0207 637 8227.

